sphingosine-1-phosphate recep. mod. prodrug
for multiple sclerosis, proj. human t1/2 of 5d
from opt. of prior S1P1 modulators
ACS Med. Chem. Lett., Aug. 11, 2020
Bristol-Myers Squibb, Princeton, NJ
“compound 3d”
1 min read
“compound 3d” is a prodrug which is phosphorylated in vivo to form a potent sphingosine-1-phopshate receptor modulator. BMS took two previous compounds into the clinic for MS with the goal of differentiating from fingolimod on safety. One potential issue for a previous compound was an overly long (12 day) half-life which could be undesirable in certain settings such as those involving drug-drug interactions. Therefore “compound 3d” was developed to have a shorter preducted human half-life of “only” 5 days.
Search By Structure
- GS-6207
- PF-06826647
- MSA-2
- SR-717
- Vixotrigine (BIIB074)
- BI-3406
- “compound 3d”
- “compound 12”
- “compound 12j”
- “compound 7f”
- DS34942424
- “compound 12”
- “compound 37”
- “compound 20”
Molecules of the Month
2023
2022
2021
2020